Search Results

There are 5812 results for: content related to: Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

  1. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue s2, May 2012, Pages: 1–26, I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad and J. Schulz

    Version of Record online : 8 MAR 2012, DOI: 10.1111/j.1365-2893.2012.01590.x

  2. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

    Journal of Viral Hepatitis

    Volume 19, Issue 2, February 2012, Pages: 120–127, J. Vermehren, S. Susser, C. M. Lange, N. Forestier, U. Karey, E. Hughes, R. Ralston, X. Tong, S. Zeuzem and C. Sarrazin

    Version of Record online : 1 MAR 2011, DOI: 10.1111/j.1365-2893.2011.01449.x

  3. Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 2, February 2012, Pages: 173–190, Olga M. Klibanov, Stephen B. Vickery, Jacqueline L. Olin, Lisa S. Smith and Shannon H. Williams

    Version of Record online : 30 JAN 2012, DOI: 10.1002/PHAR.1046

  4. You have free access to this content
    HCV Therapeutics: Approved Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26880

  5. You have free access to this content
    AASLD Abstracts

    Hepatology

    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Version of Record online : 1 OCT 2012, DOI: 10.1002/hep.26040

  6. You have free access to this content
    Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers

    Hepatology

    Volume 56, Issue 5, November 2012, Pages: 1622–1630, Ellen Hulskotte, Samir Gupta, Fengjuan Xuan, Marga van Zutven, Edward O'Mara, Hwa-Ping Feng, John Wagner and Joan Butterton

    Version of Record online : 14 OCT 2012, DOI: 10.1002/hep.25831

  7. You have free access to this content
    Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy

    Alimentary Pharmacology & Therapeutics

    Volume 32, Issue 1, July 2010, Pages: 14–28, C. M. Lange, C. Sarrazin and S. Zeuzem

    Version of Record online : 31 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04317.x

  8. Direct-acting antivirals for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Janus C Jakobsen, Emil Eik Nielsen, Joshua Feinberg, Kiran Kumar Katakam, Kristina Fobian, Goran Hauser, Goran Poropat, Snezana Djurisic, Karl Heinz Weiss, Milica Bjelakovic, Goran Bjelakovic, Sarah Louise Klingenberg, Jian Ping Liu, Dimitrinka Nikolova, Ronald L Koretz and Christian Gluud

    Published Online : 6 JUN 2017, DOI: 10.1002/14651858.CD012143.pub2

  9. You have free access to this content
    New HCV therapies on the horizon

    Clinical Microbiology and Infection

    Volume 17, Issue 2, February 2011, Pages: 122–134, J. Vermehren and C. Sarrazin

    Version of Record online : 20 JAN 2011, DOI: 10.1111/j.1469-0691.2010.03430.x

  10. You have free access to this content
    Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 1, January 2014, Pages: 93–103, L. I. Backus, P. S. Belperio, T. A. Shahoumian, R. Cheung and L. A. Mole

    Version of Record online : 10 NOV 2013, DOI: 10.1111/apt.12546

  11. You have free access to this content
    Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infection

    Hepatology

    Volume 48, Issue 5, November 2008, Pages: 1700–1712, Barbara H. McGovern, Barham K. Abu Dayyeh and Raymond T. Chung

    Version of Record online : 4 AUG 2008, DOI: 10.1002/hep.22563

  12. You have free access to this content
    Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin

    Hepatology

    Volume 56, Issue 2, August 2012, Pages: 567–575, Ira M. Jacobson, Patrick Marcellin, Stefan Zeuzem, Mark S. Sulkowski, Rafael Esteban, Fred Poordad, Savino Bruno, Margaret H. Burroughs, Lisa D. Pedicone, Navdeep Boparai, Weiping Deng, Mark J. DiNubile, Keith M. Gottesdiener, Clifford A. Brass, Janice K. Albrecht and Jean-Pierre Bronowicki

    Version of Record online : 29 JUN 2012, DOI: 10.1002/hep.25865

  13. Boceprevir in liver transplant recipients

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 192–197, Sammy Saab, Vignan Manne, Sherona Bau, Justin A. Reynolds, Ruby Allen, Leonard Goldstein, Francisco Durazo, Mohammed El-Kabany, Steven Han and Ronald W. Busuttil

    Version of Record online : 10 APR 2014, DOI: 10.1111/liv.12548

  14. Intervention of Hepatitis C Replication through NS3-4A, the Protease Inhibitor Boceprevir

    Antiviral Drugs: From Basic Discovery through Clinical Trials

    Srikanth Venkatraman, F. George Njoroge, Pages: 239–255, 2011

    Published Online : 20 JUN 2011, DOI: 10.1002/9780470929353.ch17

  15. You have free access to this content
    Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment

    Hepatology

    Volume 55, Issue 4, April 2012, Pages: 1048–1057, Patrick R. Harrington, Wen Zeng and Lisa K. Naeger

    Version of Record online : 1 MAR 2012, DOI: 10.1002/hep.24791

  16. You have free access to this content
    Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 54–60, Mitchell L. Shiffman and Rafael Esteban

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02718.x

  17. You have free access to this content
    Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects

    Journal of Gastroenterology and Hepatology

    Volume 29, Issue 8, August 2014, Pages: 1574–1581, Eric J Lawitz and Fernando E Membreno

    Version of Record online : 29 JUL 2014, DOI: 10.1111/jgh.12632

  18. Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace

    Reviews in Medical Virology

    Volume 25, Issue 4, July 2015, Pages: 254–267, Erik De Clercq

    Version of Record online : 4 JUN 2015, DOI: 10.1002/rmv.1842

  19. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy

    Journal of Viral Hepatitis

    Volume 21, Issue 4, April 2014, Pages: 229–240, D. L. Wyles and J. A. Gutierrez

    Version of Record online : 6 MAR 2014, DOI: 10.1111/jvh.12230

  20. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans

    Journal of Viral Hepatitis

    Volume 22, Issue 5, May 2015, Pages: 489–495, R. Gidwani, P. G. Barnett, J. D. Goldhaber-Fiebert, S. M. Asch, J. Lo, S. K. Dally and D. K. Owens

    Version of Record online : 24 NOV 2014, DOI: 10.1111/jvh.12344